老年急性髓性白血病(acute myeloid leukemia,AML)具有独特的生物学特征,临床表现为难治、易复发,患者对化疗耐受性差导致早期死亡率增高〔1〕。2010年,艾辉胜教授最早提出对老年AML患者采用在化疗后分次输注小量异基因造血干细胞微移植,可使老年AML的2年总生存率由对照组的11%提高至39%,认为微移植有抗白血病作用,化疗后联合异基因造血干细胞微移植可促进粒 Elderly acute myeloid leukemia (AML) has unique biological characteristics, clinical manifestations of refractory, easy to relapse, patients with poor tolerance to chemotherapy lead to increased early mortality 〔1〕. In 2010, Professor Ai Fusheng put forward the earliest proposed micro-transplantation of small amount of allogeneic hematopoietic stem cells in patients with AML after fractional infusion of chemotherapy, which can increase the 2-year overall survival rate of elderly AML from 11% in the control group to 39% , That micro-transplantation has anti-leukemia effect, combined with allogeneic hematopoietic stem cell micro-transplantation after chemotherapy can promote grain